MYIA
MDGL icon

Mount Yale Investment Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Mount Yale Investment Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Buy
438
+19
+5% +$9.73K ﹤0.01% 1087
2026
Q1 		$219K Sell
419
-405
-49% -$193K 0.01% 1018
2025
Q4 		$480K Buy
+824
New +$421K 0.02% 470
2025
Q3 		– Sell
-311
Closed -$94.1K – 1220
2025
Q2 		$94.1K Buy
+311
New +$92.7K 0.01% 672

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mount Yale Investment Advisors's MDGL Position: Q2 2026 in Review

Mount Yale Investment Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 4.5% in Q2 2026, buying an estimated $9.73K and bringing the position to 438 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #1087.

Mount Yale Investment Advisors first reported a position in MDGL in Q2 2025 and has held it in 4 quarters since. The position peaked at $480K in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Mount Yale Investment Advisors held 438 shares of Madrigal Pharmaceuticals worth $235K as of Q2 2026.
  • Mount Yale Investment Advisors bought 19 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $9.73K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Mount Yale Investment Advisors's portfolio in Q2 2026, its #1087 holding.
  • Mount Yale Investment Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Mount Yale Investment Advisors's Madrigal Pharmaceuticals position peaked at $480K in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.